eClips Consult provides evidence-graded abstracts of the most important articles in your speciality, along with expert commentary and ratings on their significance. It's the efficient way to stay current in medicine. http://eclips.consult.comen-us<![CDATA[Older women with breast cancer are underrepresented in clinical trials, and data on the effects of adjuvant chemotherapy in such patients are scant. We tested for the noninferiority of capecitabine as compared with standard chemotherapy in women with breast cancer who were 65 years of age or older.]]>http://eclips.consult.com/eclips/article/Breast Diseases/S1043-321X(10)79471-6?source=rsshttp://eclips.consult.com/eclips/article/Breast Diseases/S1043-321X(10)79471-6?source=rss04 Mar 2010Breast Diseases<![CDATA[This study compares the efficacy of three types of reminders in promoting annual repeat mammography screening.]]>http://eclips.consult.com/eclips/article/Breast Diseases/S1043-321X(10)79496-0?source=rsshttp://eclips.consult.com/eclips/article/Breast Diseases/S1043-321X(10)79496-0?source=rss04 Mar 2010Breast Diseases<![CDATA[Quantitative immunocytochemical assays of 1,200 breast carcinomas were assessed after construction of tissue microarrays. A total of 42 markers were evaluated for prognostic significance by univariate log rank test (mean follow-up, 79 months), using quantitative scoring by an image analysis device and specific software. Complete data were obtained for 924 patients, for whom 27 of the 42 markers proved to be significant prognostic indicators. Analysis of these 27 markers by logistic regression showed that 18 (cMet, CD44v6, FAK, moesin, caveolin, c-Kit, CK14, CD10, P21, P27, pMAPK, pSTAT3, STAT1, SHARP2, FYN, ER, PgR and c-erb B2), and 15 when ER, PgR and c-erb B2 were excluded, were 80.52% and 78.9% predictive of disease outcome, respectively. The immunocytochemical assays on 4 micron thick sections of fixed tissue are easy to handle in current practice and are costeffective. Quantitative densitometric measurement of immunoprecipitates by computer-assisted devices from digitized microscopic images allows standardized high-throughput “in situ” molecular profiling within tumors. It is concluded that this 15 marker immunohistochemical signature is suitable for current practice, since performed on paraffin sections of fixed tumor samples, and can be used to select patients needing more aggressive therapy, since this signature is about 80% predictive of poor clinical outcome. Also, the markers included in the signature may be indicative of tumor responsiveness to current chemotherapy or suggest new targets for specific therapies.]]>http://eclips.consult.com/eclips/article/Breast Diseases/S1043-321X(10)79487-X?source=rsshttp://eclips.consult.com/eclips/article/Breast Diseases/S1043-321X(10)79487-X?source=rss04 Mar 2010Breast Diseases<![CDATA[The axillary recurrence (AR) rate after negative sentinel node biopsy (SNB) in patients with high risk of axillary metastases is largely unknown. The aim of this study was to analyze the risk factors for isolated AR after negative SNB with special interest in large or multifocal tumors.]]>http://eclips.consult.com/eclips/article/Breast Diseases/S1043-321X(10)79492-3?source=rsshttp://eclips.consult.com/eclips/article/Breast Diseases/S1043-321X(10)79492-3?source=rss04 Mar 2010Breast Diseases<![CDATA[Radiotherapy (RT) has been a risk factor for development of soft tissue sarcomas (STS). The objective of the current study was to quantify the risk of STS after RT and surgery for breast cancer (BCa), assess time trends, and compare long-term survival of patients with RT-associated and non-RT-associated angiosarcoma (AS) using the Surveillance, Epidemiology, and End Results (SEER) database.]]>http://eclips.consult.com/eclips/article/Breast Diseases/S1043-321X(10)79476-5?source=rsshttp://eclips.consult.com/eclips/article/Breast Diseases/S1043-321X(10)79476-5?source=rss04 Mar 2010Breast Diseases<![CDATA[Expander/implant and autogenous tissue breast reconstructions have different aging processes, and the time when these processes stabilize is unclear. The authors' goal was to evaluate long-term patient-reported aesthetic satisfaction with expander/implant and autogenous breast reconstruction.]]>http://eclips.consult.com/eclips/article/Breast Diseases/S1043-321X(10)79472-8?source=rsshttp://eclips.consult.com/eclips/article/Breast Diseases/S1043-321X(10)79472-8?source=rss04 Mar 2010Breast Diseases<![CDATA[The phosphoinositide 3-kinase/Akt pathway is involved in the pathogenesis of several human cancers. In this study, the biological and prognostic value of phosphoinositide 3-kinase/Akt pathway dysregulation was assessed by immunohistochemistry in a well-characterized series of 72 patients with node-negative breast cancer with a long-term follow-up. Phosphorylated Akt and PTEN expression was reduced in 32% and 12.5% of the tumors, respectively. Phosphorylated Akt or PTEN status was not associated with the main clinicopathologic and biological parameters, whereas their expression was tightly related to their downstream targets cyclin D1 and p27Kip1 which are involved in cell proliferation. Survival analysis showed a strong association between a shorter disease-free survival and the dysregulated expression of phosphorylated Akt (P=.036), PTEN (P=.003), p27Kip1 (P=.008), and Ki67 (P=.0007), or the distinct subtypes of breast tumors (luminal, HER2 overexpressing, and basal-like; P=.03). Moreover, multivariate analysis using the Cox proportional-hazards regression model showed that PTEN and Ki67 were independent predictive factors of disease recurrence and that their simultaneous dysregulation strongly increased the hazards ratio of the patients with node-negative breast cancer (hazards ratio, 38.30; P=.0014). In conclusion, our results show that the dysregulation of the phosphoinositide 3-kinase/Akt/PTEN pathway is relevant to the prognosis in node-negative breast carcinoma and that the evaluation of key components of this pathway might be a useful tool to identify the patients with node-negative breast cancer at high-risk of disease recurrence.]]>http://eclips.consult.com/eclips/article/Breast Diseases/S1043-321X(10)79497-2?source=rsshttp://eclips.consult.com/eclips/article/Breast Diseases/S1043-321X(10)79497-2?source=rss04 Mar 2010Breast Diseases<![CDATA[To examine how care for breast cancer survivors compares with controls.]]>http://eclips.consult.com/eclips/article/Breast Diseases/S1043-321X(10)79460-1?source=rsshttp://eclips.consult.com/eclips/article/Breast Diseases/S1043-321X(10)79460-1?source=rss04 Mar 2010Breast Diseases<![CDATA[Completion axillary lymph node dissection (ALND) remains the standard of care for patients with disease-positive sentinel lymph nodes (SLN). However, approximately two-thirds will have no additional disease-positive nodes. To identify the patient's individual risk for non-SLN metastases, the Memorial Sloan-Kettering Cancer Center (MSKCC) developed a nomogram.]]>http://eclips.consult.com/eclips/article/Breast Diseases/S1043-321X(10)79493-5?source=rsshttp://eclips.consult.com/eclips/article/Breast Diseases/S1043-321X(10)79493-5?source=rss04 Mar 2010Breast Diseases<![CDATA[The addition of bevacizumab to weekly paclitaxel as primary chemotherapy for HER-2 negative metastatic breast cancer (MBC) prolongs progression-free survival without a substantial increase of toxicity.]]>http://eclips.consult.com/eclips/article/Breast Diseases/S1043-321X(10)79477-7?source=rsshttp://eclips.consult.com/eclips/article/Breast Diseases/S1043-321X(10)79477-7?source=rss04 Mar 2010Breast Diseases